Alcon Pharmaceuticals has transitioned into the broader Novartis Pharmaceuticals Corporation organization, and this website is now governed by the Novartis Pharmaceuticals Corporation Privacy Policy and Terms of Use. Click here to read the Novartis Pharmaceuticals Corporation Privacy Policy, and here to read the Novartis Pharmaceuticals Corporation Terms of Use.
PATADAY® Solution and PAZEO® Solution are indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is one drop in each affected eye once a day.
PATADAY® Solution and PAZEO® Solution are for topical ocular use only; not for injection or oral use.
As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep the bottle tightly closed when not in use.
Patients should be advised not to wear contact lenses if their eyes are red. PATADAY® Solution and PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PATADAY® Solution and PAZEO® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling PATADAY® Solution or at least five minutes after instilling PAZEO® Solution before they insert their contact lenses.
Symptoms similar to cold syndrome and pharyngitis were the two most common adverse reactions reported with the use of PATADAY® Solution, at an incidence of approximately 10%.
The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO® Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye.
For additional information about PATADAY® Solution and PAZEO® Solution, please click to view the full prescribing information.
REFERENCE:
1. PAZEO® Solution Package Insert.
Olopatadine is licensed from Kyowa Hakko Kirin Co., Ltd. Japan.
©2016 Novartis
PAY-1339821 01/2017
Novartis
REFERENCE:
1. PAZEO® Solution Package Insert.
PAY-1339821 1/17
Olopatadine is licensed from Kyowa Hakko Kirin Co., Ltd. Japan.
©2017 Novartis